文献速递血管炎

肺出血、PR3阳性及尿红细胞管型与ANCA相关血管炎静脉血栓栓塞相关

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PubMed 文献 · Arthritis Rheumatol · 2019-09-25

基于RAVE试验197例ANCA相关血管炎患者分析,静脉血栓栓塞(VTE)发生于16例(8.1%),平均发生时间1.5个月。多因素分析显示,心脏受累、PR3-ANCA阳性、肺出血和尿红细胞管型与VTE发生独立相关。

要点

  • AAV患者VTE发生率为8.1%,平均发生时间1.5个月。
  • 肺出血、PR3-ANCA阳性、心脏受累及尿红细胞管型与VTE风险升高相关。
  • 需进一步研究验证并探索高凝机制以指导治疗。

核心结论

  • 合并肺出血、PR3-ANCA阳性、心脏受累及尿红细胞管型的AAV患者发生VTE的风险增加。

研究设计与样本

  • 对RAVE试验中197例ANCA相关血管炎患者进行VTE事件分析,记录基线人口学和临床特征,行单因素和多因素分析。

主要发现

  • VTE发生于16例患者(8.1%),总体平均发生时间为1.5个月(范围1.0-2.75)。
  • 单因素分析中,心脏受累(HR 17.408 [95%CI 2.247-134.842];P=0.006)、PR3-ANCA阳性(HR 7.731 [95%CI 1.021-58.545];P=0.048)、肺出血(HR 3.889 [95%CI 1.448-10.448];P=0.008)和红细胞管型(HR 15.617 [95%CI 3.491-69.854];P<0.001)与VTE发生相关。
  • 调整年龄和性别后,VTE与心脏受累(HR 21.836 [95%CI 2.566-185.805];P=0.005)、PR3-ANCA(HR 9.12 [95%CI 1.158-71.839];P=0.036)、肺出血(HR 3.91 [95%CI 1.453-10.522];P=0.007)及尿红细胞管型(HR 16.455 [95%CI 3.607-75.075];P<0.001)的显著关联仍存在。

临床怎么用

  • 对具有肺出血、PR3-ANCA阳性、心脏受累或尿红细胞管型的AAV患者,应警惕VTE风险。

局限性

  • 需进一步研究确认和扩展这些发现,并探索高凝机制以指导治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (RAVE) trial and identify novel potential risk factors. METHODS: VTE events in 197 patients enrolled in the RAVE trial were analyzed. Baseline demographic and clinical characteristics were recorded, and univariate and multivariate analyses were performed to identify factors associated with VTE in ANCA-associated vasculitis (AAV). RESULTS: VTE occurred in 16 patients (8.1%) with an overall average time to event of 1.5 months (range 1.0-2.75). In univariate analyses with calculation of hazard ratios (HRs) and 95% confidence intervals (95% CIs), heart involvement (HR 17.408 [95% CI 2.247-134.842]; P = 0.006), positive proteinase 3 (PR3)-ANCA (HR 7.731 [95% CI 1.021-58.545]; P = 0.048), pulmonary hemorrhage (HR 3.889 [95% CI 1.448-10.448]; P = 0.008), and the presence of red blood cell casts (HR 15.617 [95% CI 3.491-69.854]; P < 0.001) were associated with the onset of VTE. In multivariate models adjusted for age and sex, the significant associations between VTE events and heart involvement (HR 21.836 [95% CI 2.566-185.805]; P = 0.005), PR3-ANCA (HR 9.12 [95% CI 1.158-71.839]; P = 0.036), pulmonary hemorrhage (HR 3.91 [95% CI 1.453-10.522]; P = 0.007), and urinary red blood cell casts (HR 16.455 [95% CI 3.607-75.075]; P < 0.001) remained. CONCLUSION: Patients diagnosed as having AAV with pulmonary hemorrhage, positive PR3-ANCA, heart involvement, and the presence of red blood cell casts are at an increased risk to develop VTE. Further studies are needed to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic intervention.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kronbichler A, Leierer J, Shin JI, et al. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019. PMID: 31216123. doi:10.1002/art.41017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。